Yamamoto T, Horikawa N, Komuro Y, Hara Y
Research Center, Sumitomo Pharmaceuticals Co., Ltd., Osaka, Japan.
Eur J Pharmacol. 1996 Apr 29;302(1-3):53-60. doi: 10.1016/0014-2999(96)00019-2.
The mechanism of wound healing induced by topical application of an ointment containing a new stable prostacyclin analogue, SM-10902 ((+)-methyl[2-[(2R,3aS,4R,5R, 6aS)-octahydro-5-hydroxy-4-[(E)-(3S,5S)-3-hydroxy-5-methyl-1- nonenyl]-2-pentalenyl] ethoxy] acetate), was investigated in the full-thickness wounds of genetically diabetic mice (db/db mice). The db/db mice treated with SM-10902 ointment (1, 10 and 100 micrograms/g) showed greater decrease in wound lesion area not covered with epidermis and fewer complete healing days than those treated with ointment base, and the effects of this prostacyclin analogue were greater than those of lysozyme chloride ointment (50 mg/g, Reflap ointment). SM-10902 ointment increased skin blood flow in the central site of the wound with development of wound healing. Histological evaluation of wounds revealed that SM-10902 ointment increased the capillary number during the early stage of the wound-healing process. These results suggest that SM-10902 ointment promotes wound healing through the stimulation of angiogenesis and the improvement of blood flow in neovascularization of repairing wound and may be useful in the treatment of skin ulcers caused by peripheral circulatory insufficiency.
在遗传性糖尿病小鼠（db/db小鼠）的全层伤口中，研究了局部应用含新型稳定前列环素类似物SM-10902（(+)-甲基[2-[(2R,3aS,4R,5R,6aS)-八氢-5-羟基-4-[(E)-(3S,5S)-3-羟基-5-甲基-1-壬烯基]-2-戊烯基]乙氧基]乙酸酯）的软膏诱导伤口愈合的机制。用SM-10902软膏（1、10和100微克/克）治疗的db/db小鼠，与用软膏基质治疗的小鼠相比，未被表皮覆盖的伤口病变面积减少得更多，完全愈合天数更少，且这种前列环素类似物的效果大于溶菌酶氯化物软膏（50毫克/克，Reflap软膏）。随着伤口愈合的进展，SM-10902软膏增加了伤口中心部位的皮肤血流量。伤口的组织学评估显示，SM-10902软膏在伤口愈合过程的早期增加了毛细血管数量。这些结果表明，SM-10902软膏通过刺激血管生成和改善修复伤口新生血管化中的血流来促进伤口愈合，可能对治疗由外周循环功能不全引起的皮肤溃疡有用。
